Cofilin-2 mRNA 3' untranslated region (CFL2 3'UTR) (CFL2 3'UTR)

Cofilin-2 (CFL2) is a muscle-specific member of the actin-depolymerizing factor (ADF)/cofilin family, essential for the regulation of actin filament dynamics in skeletal and cardiac muscle (UniProt P60981). The 3' untranslated region (3'UTR) of the CFL2 mRNA serves as a critical regulatory hub, containing binding sites for microRNAs (such as miR-1 and miR-206) and RNA-binding proteins that dictate mRNA stability and translation efficiency (PubMed: 21835157). Mutations or dysregulation of CFL2 are primarily associated with Nemaline Myopathy type 7 (NEM7), a condition marked by muscle weakness and the accumulation of actin-containing nemaline bodies (NCBI Gene: 1073). In the context of drug development, the CFL2 3'UTR is a target for RNA-based therapies, including antisense oligonucleotides (ASOs) and microRNA inhibitors, aimed at modulating protein levels to restore muscle function (PubMed: 25652404). Targeting this region allows for precise control over the post-transcriptional expression of Cofilin-2, offering a potential pathway for treating myopathies and other muscle-wasting conditions. Furthermore, the 3'UTR is involved in the spatial localization of the mRNA within the muscle fiber, which is crucial for localized protein synthesis (PubMed: 19056801). Therapeutic strategies targeting this region often focus on blocking the binding of inhibitory microRNAs to increase the production of functional Cofilin-2 protein. This approach is particularly relevant for patients with haploinsufficiency or regulatory mutations that reduce CFL2 levels without completely abolishing protein function. Safety considerations for targeting the CFL2 3'UTR include the potential for off-target effects on other mRNAs sharing similar regulatory sequences. Overall, the CFL2 3'UTR represents a sophisticated target for precision medicine in neuromuscular disorders.

Other names

CFL2 3' untranslated regionCofilin-2 3'UTRCofilin-2 3-prime UTR

Modulation of mRNA stability or translation efficiency via RNA-targeted agents